OPEN END TURBO C AUF NOVO NORDIS/ DE000HG6JQK7 /
2024-06-11 10:35:17 AM | Chg.-0.170 | Bid10:36:16 AM | Ask10:36:16 AM | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
15.660EUR | -1.07% | 15.650 Bid Size: 10,000 |
15.750 Ask Size: 10,000 |
Novo Nordisk | 58.9977 USD | 2078-12-31 | Call |
GlobeNewswire
06-10
RenovoRx Appoints Ryan Witt as Senior Vice President, Head of Corporate Strategy and Partnerships
GlobeNewswire
05-31
Zealand Pharma announces positive CHMP opinion for dasiglucagon for treatment of severe hypoglycemia...
GlobeNewswire
05-30
Anaqua Annual User Experience Conference to Feature Keynotes from Microsoft, SAP, USPTO, and More
GlobeNewswire
05-15
Veru Announces Steven B. Heymsfield M.D. as the Principal Investigator for its Enobosarm Phase 2b Cl...
GlobeNewswire
05-14
Veru Announces Mitchell Steiner as Keynote Speaker at Biomed Israel 2024: The 22nd National Life Sci...
GlobeNewswire
05-09
US Neurologists Report Route of Administration as a Critical Factor when Evaluating Future Parkinson...
GlobeNewswire
05-07
Vect-Horus to Take Part in a Roundtable Discussion at Viva Technology Conference
GlobeNewswire
04-22
Vect-Horus Publication in Pharmaceutics Outlines How Vectors Can Improve Delivery of Therapeutics to...
GlobeNewswire
04-22
SNIPR Biome receives funding from CARB-X to support advancement of CRISPR-medicine SNIPR001 into cli...
GlobeNewswire
04-22
SNIPR Biome receives funding from CARB-X to support advancement of CRISPR-medicine SNIPR001 into cli...
GlobeNewswire
04-11
Robbins LLP is Investigating the Acquisition of Catalent, Inc. (CTLT) by Novo Holdings
GlobeNewswire
04-02
Arch Biopartners Adds Three New Clinical Sites into the Phase II Trial for LSALT Peptide Targeting C...
GlobeNewswire
03-28
Omega Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Strategi...
GlobeNewswire
03-27
Aeterna Zentaris Reports Fourth Quarter and Full Year 2023 Financial Results and Announces Completio...
GlobeNewswire
03-25
Tonix Pharmaceuticals Receives Rare Pediatric Disease Designation from the FDA for TNX-2900 for the ...
GlobeNewswire
03-18
Arch Biopartners Clinical Team Publishes Data from Phase II Trial for LSALT Peptide Targeting Organ ...